Amendments to the Claims/Listing of Claims

Please amend claims 1, 2 and 3 as follows. In addition, please cancel claims 36 and 37 without prejudice. The listing of claims will replace all prior versions, and listings, of claims in the application:

(Currently amended) A method for modulating-process(es)-mediated-by farnesoid-X-receptor-polypeptides the treatment of hypercholestemia or cholestasis, said method comprising conducting-said-process(es)-in the presence of administering to a subject in need thereof an effective amount of at least one compound having the structure:

$$R^2$$
 R^3
 R^4
 N
 A
 $X \cdot OR$

wherein:

A is a C3 up to C8 branched chain alkyl or substituted alkyl group, a C3 up to C7 cycloalkyl or substituted cycloalkyl, an optionally substituted aryl or an optionally substituted heteroaryl.

X is
$$-C(O)$$
- or $-CH_{o}$ -,

R is methyl or ethyl.

R¹ is H, hydroxy, alkoxy, benzoyloxy, mesityloxy, or -OCH₂C(O)OC₂H₆,

 $\mbox{\it R}^2$ is H or $\mbox{\it R}^2$ can cooperate with $\mbox{\it R}^3$ to form a benzopyran, wherein the pyran ring has the structure:

DLMR_557451.2 -2-

wherein:

 R^{6} is not present if the pyran ring is unsaturated, or, if present, is selected from H, -OR, wherein R is alkyl or acyl, or R^{6} can cooperate with R^{7} to form a cyclic acetal, a cyclic ketal, or a cyclopropyl moiety, and

only one of R^7 and R^8 is present if the pyran ring is unsaturated, or R^7 and R^8 are independently H, carboxyl, cyano, hydroxy, alkoxy, thioalkyl, aryl, or R^7 and R^8 taken together comprise a carbonyl oxygen or an oxime nitrogen, or either R^7 or R^8 can cooperate with R^8 to form a cyclic acetal, a cyclic ketal, or a cyclopropyl moiety,

R³ can cooperate with R² to form a benzopyran having the structure set forth above, or R³ is alkenyl, optionally substituted aryl or heteroaryl, or optionally substituted arylalkenyl or heteroarylalkenyl.

R4 is H or hydroxy, and

R⁵ is H, hydroxy, alkoxy or aryloxy.

- (Currently amended) The method of claim 1 wherein said process-mediated by farnesoid—X—receptor—is—cholesterol—metabolism method comprises treatment of hypercholestemia.
- (Currently amended) The method of claim 1 wherein said process-mediated by farnesoid-X-receptor-is-the-regulation of lipid homeostasis method comprises treatment of cholestasis.

DLMR_557451.2 _3_

- 4. (Original) The method of claim 1 wherein $\mbox{\it R}^2$ and $\mbox{\it R}^3$ cooperate to form a benzopyran.
- 5. (Original) The method of claim 4 wherein A is cyclopropyl, X is -C(O)-, R^1 is methoxy, R^6 and R^7 are absent, and R^4 , R^5 and R^8 are hydrogen.
- 6. (Original) The method of claim 4 wherein A is cyclopropyl, X is $-CH_2$, R^1 is methoxy, R^6 and R^7 are absent, and R^4 , R^5 and R^8 are hydrogen.
- 7. (Original) The method of claim 4 wherein A is cyclohexyl, X is -C(O)-, R^1 is methoxy, R^8 and R^7 are absent, and R^4 , R^5 and R^8 are hydrogen.
- 8. (Original) The method of claim 4 wherein A is phenyl, X is -C(O)-, R^1 is methoxy, R^8 and R^7 are absent, and R^4 , R^8 and R^8 are hydrogen.
- 9. (Original) The method of claim 4 wherein A is phenyl, X is -C(0)-, R^1 is methoxy, R^8 and R^7 cooperate to form a dichlorocyclopropyl ring, and R^4 , R^5 and R^8 are hydrogen.
- 10. (Original) The method of claim 4 wherein A is cyclohexyl, X is -C(0) -, R^1 is methoxy, R^8 and R^7 cooperate to form a dichlorocyclopropyl ring, and R^4 , R^5 and R^8 are hydrogen.
 - 11. (Original) The method of claim 1 wherein R³ is alkenyl.
- 12. (Original) The method of claim 11 wherein A is cyclohexyl, X is -C(O)-, R^1R^2 , R^4 and R^5 are hydrogen, and R^3 is CH=CH-C(O)-O-tBu.
- 13. (Original) The method of claim 1 wherein R³ is optionally substituted aryl or heteroaryl.

DLMR_557451.2 -4-

 (Previously presented) The method of claim 13 wherein said compound is selected from the group consisting of compounds wherein:

A is cyclohexyl,

X is -C(O)-,

R¹ R², R⁴ and R⁵ are each hydrogen, and

R³ is selected from the group consisting of phenyl, p-thiomethyl-phenyl, m-methoxyphenyl, m-acetyl-phenyl, 5-methyl-2-thiophene-yl, 5-acetyl-2-thiophene-yl, 4-dimethylaminophenyl, and 2,3-(O-CH₂-O)-phenyl.

15 -20 Cancelled

21. (Previously presented) The method of claim 13 wherein said compound is selected from the group consisting of compounds wherein:

A is isopropyl,

X is -C(O)-.

R¹ R², R⁴ and R⁵ are each hydrogen, and

R³ is 4-dimethylamino-phenyl, or 2,3-(O-CH₂-O)-phenyl.

22 -23 Cancelled

- $24. \qquad \hbox{(Original) The method of claim 1 wherein R^3 is or optionally substituted arylalkenyl or heteroarylalkenyl.}$
- 25. (Previously presented) The method of claim 24 wherein said compound is selected from the group consisting of compounds wherein:

A is cyclohexyl,

X is -C(0)-, R¹ R², R⁴ and R⁵ are each hydrogen, and

R³ is selected from the group consisting of –CH=CH-phenyl, –CH=CH-p-methoxyphenyl, – CH=CH-o-fluoro-phenyl, –CH=CH-m-fluoro-phenyl, and –CH=CH-p-fluoro-phenyl.

DLMR_557451.2 -5-

Atty. Dkt. No. SALK3130-1S (088802-9706)

26. (Previously presented) The method of claim 24 wherein said compound is selected from the group consisting of compounds wherein:

A is isopropyl,

X is -C(O)-,

 $R^{1}R^{2}$, R^{4} and R^{5} are each hydrogen, and

R³ is selected from the group consisting of –CH=CH-phenyl, –CH=CH-o-fluoro-phenyl, -CH=CH-m-fluoro-phenyl, and –CH=CH-p-fluoro-phenyl.

27.-37. Cancelled.

DLMR_557451.2 -6-